Unknown

Dataset Information

0

LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.


ABSTRACT: Immune checkpoint blockade therapy has been successful in treating some types of cancer but has not shown clinical benefits for treating leukaemia1. This result suggests that leukaemia uses unique mechanisms to evade this therapy. Certain immune inhibitory receptors that are expressed by normal immune cells are also present on leukaemia cells. Whether these receptors can initiate immune-related primary signalling in tumour cells remains unknown. Here we use mouse models and human cells to show that LILRB4, an immunoreceptor tyrosine-based inhibition motif-containing receptor and a marker of monocytic leukaemia, supports tumour cell infiltration into tissues and suppresses T cell activity via a signalling pathway that involves APOE, LILRB4, SHP-2, uPAR and ARG1 in acute myeloid leukaemia (AML) cells. Deletion of LILRB4 or the use of antibodies to block LILRB4 signalling impeded AML development. Thus, LILRB4 orchestrates tumour invasion pathways in monocytic leukaemia cells by creating an immunosuppressive microenvironment. LILRB4 represents a compelling target for the treatment of monocytic AML.

SUBMITTER: Deng M 

PROVIDER: S-EPMC6296374 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.

Deng Mi M   Gui Xun X   Kim Jaehyup J   Xie Li L   Chen Weina W   Li Zunling Z   He Licai L   Chen Yuanzhi Y   Chen Heyu H   Luo Weiguang W   Lu Zhigang Z   Xie Jingjing J   Churchill Hywyn H   Xu Yixiang Y   Zhou Zhan Z   Wu Guojin G   Yu Chenyi C   John Samuel S   Hirayasu Kouyuki K   Nguyen Nam N   Liu Xiaoye X   Huang Fangfang F   Li Leike L   Deng Hui H   Tang Haidong H   Sadek Ali H AH   Zhang Lingbo L   Huang Tao T   Zou Yizhou Y   Chen Benjamin B   Zhu Hong H   Arase Hisashi H   Xia Ningshao N   Jiang Youxing Y   Collins Robert R   You M James MJ   Homsi Jade J   Unni Nisha N   Lewis Cheryl C   Chen Guo-Qiang GQ   Fu Yang-Xin YX   Liao X Charlene XC   An Zhiqiang Z   Zheng Junke J   Zhang Ningyan N   Zhang Cheng Cheng CC  

Nature 20181017 7728


Immune checkpoint blockade therapy has been successful in treating some types of cancer but has not shown clinical benefits for treating leukaemia<sup>1</sup>. This result suggests that leukaemia uses unique mechanisms to evade this therapy. Certain immune inhibitory receptors that are expressed by normal immune cells are also present on leukaemia cells. Whether these receptors can initiate immune-related primary signalling in tumour cells remains unknown. Here we use mouse models and human cell  ...[more]

Similar Datasets

| S-EPMC7052276 | biostudies-literature
| S-EPMC3750496 | biostudies-literature
| S-EPMC4942573 | biostudies-literature
| S-EPMC4354161 | biostudies-literature
| S-EPMC6617595 | biostudies-literature
| S-EPMC6677629 | biostudies-literature
| S-EPMC4205848 | biostudies-literature
| S-EPMC5817239 | biostudies-literature
| S-EPMC5727250 | biostudies-literature
| S-EPMC2413189 | biostudies-literature